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Over the last 7 years, we have focused our experimental and computational research efforts 
on improving our understanding of the biochemical, molecular, and cellular processing of 
iododeoxyuridine (IUdR) and ionizing radiation (IR) induced DNA base damage by DNA mismatch 
repair (MMR). These coordinated research efforts, sponsored by the National Cancer Institute 
Integrative Cancer Biology Program (ICBP), brought together system scientists with expertise 
in engineering, mathematics, and complex systems theory and translational cancer researchers 
with expertise in radiation biology. Our overall goal was to begin to develop computational 
models of IUdR- and/or IR-induced base damage processing by MMR that may provide new 
clinical strategies to optimize IUdR-mediated radiosensitization in MMR deficient (MMR−) 
“damage tolerant” human cancers. Using multiple scales of experimental testing, ranging 
from purified protein systems to in vitro (cellular) and to in vivo (human tumor xenografts in 
athymic mice) models, we have begun to integrate and interpolate these experimental data 
with hybrid stochastic biochemical models of MMR damage processing and probabilistic cell 
cycle regulation models through a systems biology approach. In this article, we highlight the 
results and current status of our integration of radiation biology approaches and computational 
modeling to enhance IUdR-mediated radiosensitization in MMR− damage tolerant cancers.
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of clinically active chemotherapy drugs (Stojic et al., 2004; Jiricny, 
2006; Modrich, 2006; Kinsella, 2009) as well as to other types of 
DNA damage (stress) including ionizing radiation (IR; Yan et al., 
2001, 2009; Brown et al., 2003; Cejka et al., 2004) and hypoxia 
(Kondo et al., 2001; Mihaylova et al., 2003; Koshiji et al., 2005; 
Klein and Glazer, 2010). Interestingly, promoter hypermethylation 
of hMLH1 and hMSH2 genes and subsequent loss of MMR protein 
expression was found in nearly 50% of NSCL cancers occurring 
in non-smokers and was associated with a poor prognosis even in 
early stage lung cancers (Hsu et al., 2005). However, MSI-H local-
ized colon cancers appear to have a better prognosis than MMR 
proficient (MMR+) tumors following surgery (Lynch and de la 
Chapelle, 2003; Peltomaki, 2003). These conflicting clinical data 
underscore the biological complexity of MMR and its translational 
importance to cancer therapeutics.
The MMR pathway is a multiprotein system that has three sub-
processes (Lynch and de la Chapelle, 2003; Jiricny, 2006; Kinsella, 
2009). These sub-processes involve: first, mismatch recognition 
by MutSα (a MSH2/MSH6 dimer) or MutSβ (a MSH2/MSH3 
dimer); second, mismatch excision, which is initiated by the bind-
ing of MutLα (a MLH1/PMS2 dimer) or MutLβ (a MLH1/MLH3 
dimer) to MutSα and the subsequent recruitment of an exonuclease 
(EXO1) that sequentially removes nucleotides between an adjacent 
single-strand break (SSB) up to and beyond the mismatch on the 
I. IntroductIon
ScIentIfIc and clInIcal ratIonale for targetIng “ct-and 
Ir-reSIStant” MMr defIcIent huMan cancerS
DNA mismatch repair (MMR) is a highly conserved but complex 
DNA repair system that ensures genomic stability on several levels 
including: correcting mismatches generated during DNA replica-
tion; blocking genetic recombination events between divergent 
DNA sequences; and mediating cell death in response to certain 
DNA damaging agents (Jiricny, 2006). MMR deficiency is prin-
cipally associated with the autosomal dominant hereditary non-
polyposis colorectal cancer (HNPCC) syndrome, resulting from 
MMR gene mutations including the hMLH1, hMSH2, hMSH6, 
and hPMS2 genes (Lynch and de la Chapelle, 2003). MMR defi-
ciency is also associated with an increasing number of sporadic 
microsatellite-instability-high (MSI-H) solid tumors, principally 
related to promoter methylation of hMLH1 or hMSH2 genes 
(Peltomaki, 2003). These sporadic MSI-H cancers include several 
types of GI cancers (gastric, pancreatic, esophageal, colorectal), 
GYN cancers (endometrial, ovarian), GU cancers (bladder, ureter) 
as well as non-small cell lung (NSCL) cancers, and high grade pri-
mary brain tumors, where MMR deficiency (MSI-H phenotype) 
is found in up to 10–20% of these common cancers (Peltomaki, 
2003). Importantly, MMR deficiency is associated with in vitro/
in vivo “damage tolerance” (resistance) to multiple different classes 
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that analysis of the levels of MLH1 and MSH2 expression prior 
to chemotherapy with temozolomide may help predict treatment 
responses in patients with newly diagnosed malignant gliomas 
(Friedman et al., 1998). In this clinical study, patients with MMR− 
malignant gliomas showed a markedly reduced response rate and 
survival compared to patients with MMR+ gliomas. Importantly, the 
use of radiation therapy and concomitant temozolomide (TMZ) 
followed by monthly maintenance TMZ is now the standard of care 
in patients with glioblastoma (Stupp et al., 2005). Indeed, somatic 
point mutations in hMSH6 are found in up to 30% of recurrent/
progressive glioblastomas, which were not present in pre-treatment 
specimens. Inactivation of hMSH6 was correlated with prior or 
ongoing TMZ exposure and resulted in enhanced tumor growth 
and shorter survival (Cahill et al., 2007).
Prior studies in ovarian cancer cell lines suggest that treatment 
with platinum compounds “selects” for surviving cells with lower 
MMR protein expression or loss of MMR Brown et al. (1997). A sig-
nificant decrease in expression of both MSH2 and MLH1 proteins 
after cisplatinum chemotherapy was found in patients with spo-
radically arising ovarian tumors (Samimi et al., 2000). Decreased 
protein expression of MLH1 following adriamycin-based chemo-
therapy in breast cancer patients was also reported to correlate 
significantly with a reduced disease-free survival (p = 0.0025), 
(Mackay et al., 2000) indicating that the resistance that MMR defi-
ciency imparts to many cancer chemotherapy agents is clinically 
relevant. Analyses of the use of fluoropyrimidine-based adjuvant 
chemotherapy in patients with MMR− (microsatellite-instability-
high, MSI-H) colon and esophageal cancers showed significantly 
less benefit in disease-free survival in comparison to a significant 
benefit in patients with MMR+ colon and esophageal cancers. (Kishi 
et al., 2003; Ribic et al., 2003; Sargent et al., 2010) Additionally, 
MMR− endometrial and rectal cancers show reduced local control 
and pathologic response rates following radiation therapy alone 
(Bilbao et al., 2010) or with 5-fluorouracil-radiation therapy 
combined modality treatment, (Choi et al., 2007) respectively. In 
contrast, we have demonstrated that these MMR− “drug and IR 
resistant” human cancers show enhanced IUdR–DNA incorpora-
tion and increased IUdR (IPdR)-mediated radiosensitization using 
experimental in vitro/in vivo models.(Berry and Kinsella, 2001; Seo 
et al., 2004, 2005; Kinsella et al., 2007, 2008) The results of these 
experimental data will be reviewed below.
ScIentIfIc and clInIcal ratIonale for the uSe of Iudr and ItS 
oral prodrug, Ipdr, aS radIoSenSItIzerS In MMr defIcIent 
huMan cancerS
IUdR is a halogenated thymidine analog and has been recognized 
as an in vitro/in vivo and potential clinical radiosensitizer for sev-
eral decades (Kinsella, 1996). Following active nucleoside transport 
across cell membranes, IUdR is sequentially phosphorylated to 
IdUTP and incorporated into DNA in competition with thymi-
dine triphosphate (dTTP; Kinsella, 1996). The biochemical mecha-
nisms of cellular radiosensitization are related to the generation of 
highly reactive free radicals by IR from IUdR–DNA incorporation 
resulting in enhanced IR-induced DNA strand breaks [both single 
(SSB) and double strand (DSB)] while also altering IR damage 
repair (Kinsella, 1996). The extent (%) of thymidine replacement 
by IUdR in DNA is generally recognized to correlate directly with 
daughter DNA strand; and third, resynthesis and ligation initiated 
by DNA polymerase δ along with at least two other proteins, pro-
liferating cell nuclear antigen (PCNA) and replication protein A 
(RPA), followed by sealing the nick located in the daughter strand 
by a DNA ligase.
“Damage tolerance” (drug-resistance) has been demonstrated 
in MMR deficient (MMR−) human and murine cells to methylat-
ing agents such as temozolomide, dacarbazine, and procarbazine; 
platinum analogs including cisplatinum and carboplatinum; 
anthracyclines such as adriamycin; and nucleoside analogs such 
as 6-thioguanine (6-TG), iododeoxyuridine (IUdR), and the fluoro-
pyrimidines [both 5-fluorouracil (5-FU) and 5-fluorodeoxyuridine 
(FUdR)] (Berry et al., 1999, 2000, 2003; Meyers et al., 2001, 2003; 
Yan et al., 2003; Jiricny, 2006; Modrich, 2006; Kinsella, 2009). IR 
resistance in MMR− cells is also found, particularly using low dose 
rate (LDR)–IR (Yan et al., 2009). Based on biochemical and molecu-
lar analyses, MMR proteins (principally the MutSα complex) have 
been shown to recognize a majority of these chemically modified 
“mispairs.” However, these chemically or IR modified DNA bases 
will not be removed during the DNA degradation step of MMR 
unless they are present in the strand containing the discontinuity 
(i.e., the daughter strand). In the absence of functional MMR, cells 
do not “see” these chemically or IR modified bases in their DNA and 
continue to replicate; accumulating mutations in DNA as a result.
Following recognition of a drug or an IR-induced adduct in 
DNA, MMR+ cells may undergo a cytotoxic (cell death) response. 
It is still unclear whether this response is directly caused by the 
MMR machinery initiating a signaling cascade directing the cells 
to either repair the mismatch or undergo cell death (general dam-
age sensor model of MMR), or whether this toxicity is indirect due 
to futile attempts by MMR to repair the DNA containing a drug 
or IR-induced structural adduct in the template (parent strand) 
consistent with the futile cycle repair model of MMR (Stojic et al., 
2004; Jiricny, 2006; Modrich, 2006). Typically, MMR+ cells display a 
prolonged G
2
 cell cycle arrest and a subsequent cytotoxic response 
following two or more rounds of DNA replication after exposure 
to drugs such as temozolomide, 6-TG, and the fluoropyrimidines 
(5-FU, FdUrd; Meyers et al., 2001, 2003; Yan et al., 2003; Stojic et al., 
2004; Jiricny, 2006; Kinsella, 2009). These temporal observations 
may indicate that the MMR proteins recognize altered mismatches 
resulting from subsequent rounds (>2) of replication of DNA con-
taining the adducts, rather than the initial adducts formed by the 
incorporation or interaction of these drugs and IR with DNA.
Regardless of the mechanism by which MMR mediates a 
cytotoxic response in cells to the many different types of drug or 
IR-induced DNA adducts, deficiency in MMR (MMR−) results in a 
“damage tolerance” or “drug and IR-resistance” phenotype, which 
may have direct implications for the success of chemotherapy as 
well as fluoropyrimidine- and/or platinum-based radiosensitiza-
tion in the clinic. There are an increasing number of examples in 
the literature of clinically relevant chemotherapy, radiotherapy, or 
chemotherapy + radiotherapy “resistance” in MMR− human can-
cers. For example, in a human glioblastoma multiforme tumor 
xenograft model, loss of MMR following treatment with procar-
bazine was found to confer resistance to temozolomide, MNNG, 
and busulfan, in addition to procarbazine (Friedman et al., 1997). 
A follow-up clinical study by the same investigators has suggested 
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signaling following MMR processing. Currently, we hypothesize 
that the differences in MMR processing support both a futile cycle 
repair model for MMR in 6-TG-DNA processing and a general 
damage sensor model for MMR in IUdR–DNA processing. These 
hypotheses are supported by experimental data and mathemati-
cal models reported by our group (Yamane et al., 2004, 2007; Yan 
et al., 2004; Yamane and Kinsella, 2005; Seo et al., 2006; Gurkan 
et al., 2007a; Zeng et al., 2007; Zeng and Kinsella, 2008) and briefly 
summarized as follows.
MMr proceSSIng of 6-tg-Induced dna baSe daMage
We have previously shown that MMR+ cells are highly sensitive to 
cytotoxicity (>2–3 log cell kill) to 6-TG treatment compared to 
MMR− cells, with MMR+ cells showing an initial prolonged G
2
/M 
arrest followed by cell death after several cell replication cycles fol-
lowing 6-TG treatment (Berry et al., 1999, 2000; Yan et al., 2003). 
6-TG is known to be incorporated into DNA in human cells in place 
of dGTP during the first S-phase and a small amount (∼1 per 104 
bases) of incorporated 6-TG is rapidly methylated in situ to 6-thio-
methylguanine (6-meTG) by endogenous S-adenosylmethionine 
(Swann et al., 1996). During the next replication cycle (without fur-
ther 6-TG exposure), 6-meTG on the parental strand can pair with 
either a cytosine or a thymine and both 6-meTG:C and 6-meTG:T 
mispairs are recognized by MMR (Swann et al., 1996). According 
to the futile repair cycle model, MMR then recognizes these mis-
matches and initiates repair of the daughter strand causing a SSB 
(Yamane et al., 2004; Yan et al., 2004; Jiricny, 2006). Because 6-meTG 
in the parental strand is not removed, MMR repeatedly processes 
this damage at the same site, leading to confined SSB formation in 
the daughter strand to activate a G
2
/M checkpoint signaling cascade. 
Using an isogenic pair of MMR+ and MMR− human colon cancer 
cell lines, we previously demonstrated that more SSBs (but not 
DSBs) were produced in the MMR+ tumor cells at later times (after 
several cell doublings) following 6-TG treatment (Yan et al., 2003). 
The time course of SSB formation was temporally correlated with 
the time course of the 6-TG-induced G
2
/M arrest, which increased 
later (2–6 days), not earlier, after 6-TG removal in MMR+ cells (Yan 
et al., 2003). Thus, we argued that the formation of SSBs should 
be considered as a secondary signal produced by MMR processing 
after recognition of the primary signal, i.e., 6-meTG:C or 6-meTG:T 
mispairs. Additionally, we speculated that the continued formation 
of SSBs provides a link to the subsequent G
2
/M signaling.
In our follow-up studies of MMR futile cycle processing of 
6-TG, (Yamane et al., 2004; Yan et al., 2004) we demonstrated that 
the ATR/Chk1 pathway is responsible for the delayed (2–3 days) 
signaling of the MMR-mediated G
2
 arrest following 6-TG treat-
ment. Using chemical inhibitors and small interfering RNA (siRNA) 
knockdown of ATR and Chk1, we showed that the damage signaling 
kinases ATR and Chk1 increase within 1 day following 6-TG treat-
ment and correlate temporally with a G
2
 arrest (Yan et al., 2004). 
In contrast, Chk2 (another cell cycle kinase) increased gradually 
over 2–6 days following 6-TG treatment, which correlated with a 
later increased tetraploid (4C) G
1
 arrest. Thus, our simplified cur-
rent model of MMR processing of 6-TG (Figure 1) suggests that 
a MMR-mediated 6-TG-induced G
2
 arrest is ATR/Chk1 depend-
ent but ATM/Chk2 independent. Both apoptotic (type 1) and 
autophagic (type 2) programmed cell death pathways are activated 
the extent (%) of radiosensitization. Targeted radiosensitization by 
IUdR of certain human cancers has been tested based on the higher 
proliferation rate in these cancers compared to adjacent normal 
tissues. In our prior in vivo pre-clinical studies using daily oral or 
continuous intravenous infusions of IUdR for 4–10 days prior to 
short course IR (four fractions/4 days), we noted enhanced radio-
sensitization (1.3–1.5× compared to IR alone) but also increased 
% IUdR–DNA incorporation in both bone marrow and intestine 
(Kinsella et al., 1996). Clinically, systemic acute toxicities to bone 
marrow and intestine limited the duration and total dose of con-
tinuous intravenous infusions of IUdR during fractionated external 
beam radiation therapy (Epstein et al., 1994; Schulz et al., 2004).
IPdR is a pyrimidinone nucleoside, which was originally synthe-
sized as an antiviral agent, based on the hypothesis that nucleosides 
without an amino- or keto-group at position four of the pyrimidine 
ring would be used as a substrate of viral thymidine kinase (TK) but 
not mammalian TK (Saif et al., 2007). However, these same investi-
gators subsequently found that IPdR could be efficiently converted 
to IUdR by an aldehyde oxidase that was mainly localized to rodent 
liver (Saif et al., 2007). Subsequently, we have demonstrated that 
an aldehyde oxidase in normal liver tissue in rodents (mice, rats) 
and non-rodent animals (ferrets, monkeys) rapidly converts IPdR 
to IUdR in vivo as well as showing similar IPdR metabolism using 
cytosolic extracts of normal human liver in vitro (Kinsella et al., 
1994, 1998). We have also reported that oral IPdR can significantly 
improve the therapeutic index of IUdR-mediated radiosensitiza-
tion, compared to continuous infusion IUdR using human colo-
rectal and glioblastoma tumor xenograft models (Kinsella et al., 
1994, 1998, 2000a,b). The extent (%) of IUdR–DNA incorporation 
in small intestine and bone marrow were remarkably reduced with 
similar or superior % IUdR–DNA incorporation in the human 
tumor xenografts using oral IPdR given once daily × 14 days com-
pared to the maximum tolerated dose of IUdR as a continuous 
infusion (Kinsella et al., 1994, 1998, 2000a,b).
As part of our ICBP investigations, we have shown that IUdR 
(and IPdR) cytotoxicity are affected by both MMR and base exci-
sion repair, with both DNA repair systems capable of recognizing 
G:IU mispairs (Kinsella, 2009). We have also demonstrated that 
MMR− cells retain higher levels of IUdR–DNA incorporation using 
isogenic in vitro and in vivo models, which results in enhanced 
radiosensitization in MMR− vs. MMR+ cancers (Kinsella, 2008). As 
such, we are now developing IPdR as a potential clinical radiosen-
sitizer for MMR− and other “IR-resistant” cancers in collaboration 
with the National Cancer Institute. One goal of the development 
of in silico (computational) models of MMR processing of both 
IUdR and IR (as detailed below) is to provide insights for clinical 
trial design to optimize the dosing schedule for orally administered 
IPdR for IUdR-mediated radiosensitization in MMR− and other 
IR-resistant human cancers (Kinsella, 2008, 2009).
II. overvIew and IntegratIon of bIocheMIcal, 
Molecular, and cellular data on MMr proceSSIng of 
nucleoSIde drug (Iudr vS. 6-tg) daMage and Ir 
daMage
We are interested in studying the differences in biochemical and 
molecular MMR processing of two different nucleoside analogs 
(IUdR and 6-TG) as well as the subsequent cell cycle and cell death 
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kinase, and then is sequentially phosphorylated to IdUTP which 
competes directly with dTTP for DNA incorporation during the 
first replication following drug exposure (Figure 2; Kinsella, 1996, 
2009). Using MMR+/MMR− isogenic matched human tumor and 
mouse MEF cell lines and clinically relevant IUdR drug concen-
trations (1–10 μM) for treatment times of <1 cell doubling time, 
we found a 2–3 fold higher % IUdR–DNA incorporation in the 
MMR− vs. MMR+ cells immediately following drug exposure with 
little subsequent cytotoxicity (< <1 log) and no G
2
 cell cycle delay 
(Berry et al., 1999, 2000; Seo et al., 2006; Gurkan et al., 2007a). 
Additionally, the increased % IUdR–DNA incorporation persisted 
for several cell population doublings following IUdR treatment in 
MMR− cells without any delayed cytotoxicity compared to isogenic 
MMR+ cells, consistent with a post-replicative MMR processing 
which can repair (remove) IUdR–DNA incorporation in MMR+ 
cells similar to mismatched bases (e.g., G-T).
These in vitro results were initially surprising because IUdR 
would not be expected to result in a DNA mismatch following 
incorporation. Since the iodine atom is substituted at the five posi-
tion of the pyrimidine ring, IUdR is not different from thymidine 
in its ability to form hydrogen bonds (Freese, 1959). However, it 
has been shown previously that mispairs can be generated during 
replication across DNA containing halogenated thymidine ana-
logs like IUdR, including G:IU and A:IU mispairs (Rydberg, 1977). 
These data led us to hypothesize a general DNA damage sensor 
model for MMR processing of IUdR (Figure 2) that differs from 
futile cycling MMR processing of 6-TG (Figure 1). Additionally, 
based on the higher levels of IUdR–DNA incorporation in MMR− 
using p53-dependent and p53- independent mechanisms (Yamane 
et al., 2004, 2007; Yan et al., 2004; Yamane and Kinsella, 2005; Zeng 
et al., 2007; Zeng and Kinsella, 2008). More recently, we have shown 
that 6-TG-induced autophagy by MMR processing is positively 
regulated by both BNIP3 and mTOR/S6K1 activation (Zeng and 
Kinsella, 2008, 2010). Additionally, an ATM- and ATR-independent 
activation of Chk2 appears involved in a later 4C G
1
 arrest, which 
blocks cells that escape from the initial G
2
 checkpoint arrest fol-
lowing 6-TG treatment. We speculate that the formation of a 4C 
G
1
 cell population may also contribute to the enhanced cell death 
by senescence in MMR+ cells following 6-TG treatment.
The time course and the biologic components involved in our 
current model of the biochemical and molecular processing of 
6-TG damage in a MMR+ human colon cancer cell line, based on 
our experimental data, (Yamane et al., 2004, 2007; Yan et al., 2004; 
Yamane and Kinsella, 2005; Zeng et al., 2007; Zeng and Kinsella, 
2008) are presented in Figure 1.
MMr proceSSIng of Iudr-Induced dna baSe daMage
In contrast to our experimental data on MMR processing of 6-TG 
(Figure 1), we found that MMR processing of IUdR–DNA damage 
results in modest cytotoxicity without a significant G
2
 cell cycle 
arrest and the time course of repair is reduced, i.e., over the initial 
1–2 cell cycles following IUdR exposure, based on in vitro data using 
various isogenically matched human tumor and murine knock-
out cell lines for both MSH2 and MLH1 genes/proteins (Berry 
et al., 1999, 2000, 2003). Biochemically, IUdR is rapidly converted 
intracellularly to IdUMP by the rate limiting enzyme, thymidine 
Figure 1 | (A) cellular metabolism of 6-TG (B) current experimental biology futile cycle model of MMR processing of 6-TG-induced DNA base damage in MMR* 
cells.
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of IUdR–DNA and MSH2 protein (part of the MutSα heterodimer) 
in discrete nuclear foci in synchronized MMR+ human tumor cells 
following IUdR treatment in vitro (Berry et al., 2003). These results 
were the first demonstration of recognition of IUdR–DNA mispairs 
by MMR and confirm our prior data showing lower% IUdR–DNA 
levels in MMR+ vs. MMR− cells during and following IUdR treat-
ment (Berry et al., 1999, 2000).
We also found that MutSα has very little binding affinity for 
A:IU, C:IU, or T:IU mispairs in the same sequence context, sug-
gesting that MMR is not involved in processing these other pos-
sible IU mispairs in DNA (Berry et al., 2003). These protein data 
are consistent with our previous cellular data, in which we found 
that, although the levels of IUdR–DNA decrease over several cell 
population doublings in MMR+ cells, approximately 5% of the % 
thymidine substitution by IUdR remained (Berry et al., 1999, 2000). 
Thus, it is likely that IUdR pairs with other bases in addition to 
G:IU and we speculate that these other pairs (e.g., A:IU) are not 
recognized nor processed by MMR.
However, we also note some similarity in MMR processing of 
G:IU mispairs compared to MMR processing of 6-TG-DNA mis-
pairs. In another in vitro study, (Seo et al., 2006) we found that the 
concomitant or sequential use of chemical inhibitors of ATR (caf-
feine) and of Chk1 (UCN-01) or the use of MMR+ but ATR− (by 
siRNA knockdown) cells can alter processing of IUdR–DNA incor-
poration, resulting in a IUdR-dose-dependent increase in DNA SSB 
formation (by alkaline comet assay) and a persistence of high% 
(e.g., MMR− or MSI-H human cancers) cells compared to MMR+ 
(e.g., normal proliferating tissues such as bone marrow) cells, we 
predicted a potential therapeutic gain for IUdR-mediated radio-
sensitization in MMR− human tumors, (Kinsella, 1996) that we 
demonstrated in vivo using an athymic mouse model with simul-
taneously implanted MMR+ and MMR− human colon cancer xeno-
grafts (Seo et al., 2004).
In a purified protein study, (Berry et al., 2003) we examined 
more direct interactions between MutSα and IUdR–DNA incor-
poration by testing the ability of human MutSα (the hMSH2/
hMSH6 dimer involved in initial mismatch recognition) to bind 
to double-stranded DNA containing the physiologically relevant 
base mispairs A:IU and G:IU as well the two other possible mis-
pairs, C:IU and T:IU. Using an electrophoretic mobility shift assay 
(EMSA) analysis, we found MutSα (but not MutSβ) “recognized” 
the G:IU mispair with high affinity (> than a G:T mispair in the 
same sequence context; Berry et al., 2003). From a biochemical 
perspective, of the possible pairings between Watson–Crick bases 
and IUdR, a G:IU would bear the greatest similarity to a G:T mis-
match in DNA. However, the van-der-Waals radius of iodine is just 
slightly larger than that of the methyl group in the 5 position of 
thymidine, (Kinsella, 1996) which may cause a greater distortion 
of the DNA helix containing G:IU than would a G:T mismatch. 
This may explain the higher affinity of MutSα for G:IU than G:T 
in the same sequence context as we published (Berry et al., 2003). 
Using confocal microscopy, we also demonstrated co-localization 
Figure 2 | (A) cellular metabolism of IUdR (B) current experimental biology general damage sensor model of MMK processing of lUdR.
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response of MMR deficiency to 6-TG treatment as manifested by 
an increased cell survival and a decreased G
2
 arrest. We also found 
that, following HDR IR, the MSH2−, MMR− HEC59 cells exhibited a 
reduced and a shorter G
2
 arrest compared to the MMR+ HEC59/2–4 
cells. The findings that both MLH1 deficiency and MSH2 deficiency 
exert the same effect on G
2
 arrest after HDR IR indicate that defec-
tive MMR partially impairs a HDR IR-induced G
2
 arrest following 
IR damage. We also showed that there are no differences in the G
1
 
or S-phase cell cycle responses following IR in these isogenic pairs 
of MMR− and MMR+ cells.
IR is recognized to cause a large variety of DNA damage includ-
ing DSBs, SSBs, cross-links, and oxidative base damage. A hypoth-
esis that MMR is involved in the repair of IR-induced DNA damage 
has been proposed by our group and several others (Fritzell et al., 
1997; Davis et al., 1998; DeWeese et al., 1998; Zeng et al., 2000; 
Yan et al., 2001, 2009; Brown et al., 2003; Cejka et al., 2004). These 
reports suggest that MMR may recognize and process IR-induced 
DNA mispairs formed during DNA replication that contain oxi-
dative-damaged bases, such as 8-oxoguanine, which can mispair 
with thymine or adenine. MMR can recognize and remove these 
mispairs (Chang et al., 2002). Additionally, it was shown that non-




 inactivate both single base-pair mismatch 
and insertion-deletion loop repair activities of MMR in a dose-
dependent fashion and that inactivation is most likely due to oxi-
dative damage (Chang et al., 2002).
In our studies, (Davis et al., 1998; Yan et al., 2001) we also found 
that the extent and time course of tyrosine15-phosphorylation 
of cdc2 differs following HDR IR in MMR− vs. MMR+ cells. For 
up to one cell doubling time post-IR, phospho-Tyr15-cdc2 was 
increased in both MMR+ and MMR− cell lines, corresponding to 
the peak G
2
 arrest. However, the levels of phospho-Tyr15-cdc2 in 
the MMR− cell lines were lower compared to the MMR+ cell lines, 
again correlating with the difference in G
2
 peak between MMR− and 
MMR+ cells. After approximately 2 cell doubling times post-IR, 
levels of phospho-Tyr15-cdc2 decreased markedly in the MMR− 
cell lines, corresponding temporally to the loss of G
2
 arrest, while 
the levels of phospho-Tyr15-cdc2 remained high in the MMR+ cell 
lines. Based on these observations, we speculate the MMR system 
might help mediate an IR-induced G
2
 arrest by interacting with 
other proteins (not p53) that activate the cdc2 signaling pathway 
or MMR might interact directly with one or more components 
of the cdc2 signaling pathway. We speculate that MSH2 senses 
certain IR-induced DNA damage (e.g., oxidative damage) and 
MLH1 relays this damage signal to other proteins to regulate the 
cdc2 pathway.
Clonogenic survival following HDR IR (1–4 Gy/min) showed no 
marked differences between MMR+ and MMR− cells in the murine 
cells and human tumor cell model systems used in our studies 
and others (Fritzell et al., 1997; Davis et al., 1998; DeWeese et al., 
1998; Zeng et al., 2000; Yan et al., 2001, 2009; Brown et al., 2003; 
Cejka et al., 2004). However, a much larger survival difference 
(>1 log cell kill) was found in MMR− vs. MMR+ human tumor 
cells following LDR IR (1–18 cGy/hr continuously for 24–96 h; 
Yan et al., 2009). In this LDR study, which mimics IR dose rates 
used clinically in prostate cancer brachytherapy, we found signifi-
cant IR-resistance in MMR− cells with a reduced G
2
/M arrest and 
enhanced HPRT gene mutation rates. In contrast, MMR+ tumor 
IUdR–DNA levels following IUdR treatment. Nevertheless, using 
clinically relevant IUdR concentrations (1–10 μM) in these modi-
fied cell lines, we still did not observe any significant G
2
 cell cycle 
delay nor cell death in the next 2 days following IUdR treatment 
(Seo et al., 2006). However, exposure to higher IUdR concentra-
tions (>30 μM) results in modest cytotoxicity (by apoptosis and 
autophagy) and a G
2
 cell cycle delay. Our simplified current model 
and time course of this “general damage sensor” MMR processing 
of IUdR–DNA damage are detailed in Figure 2.
MMr proceSSIng of Ir-Induced dna baSe daMage
We have previously reported that the MLH1−, MMR− human colon 
carcinoma HCT116 cell line and MLH1−, MMRnull mouse embry-
onic fibroblast EF5 cells show a reduced and shorter G
2
 arrest after 
high dose rate (HDR; 2–4 Gy/min) IR compared to their matched 
MLH1+, MMR+ cells. The MMR− cells also showed a modest reduced 
clonogenic survival (Davis et al., 1998). In a follow-up publica-
tion, we extended our initial findings to two additional matched 
MLH1− and MLH1+ human tumor cell lines, A2780/CP70 and RKO 
(Yan et al., 2001). The human ovarian cancer cell model (A2780/
CP70) was previously established by Brown et al. (2003) while we 
established the in vitro human colon cancer model (RKO) using 
azacytidine, a demethylating agent, to result in increased MLH1 
protein expression in RKO (MLH1−, MMR−) cells. These data con-
firmed our previous finding that the expression of MLH1 protein 
(establishing a MMR+ phenotype) results in a robust IR-induced 
G
2
 arrest, which is higher (up to 80% of cell population) and more 
sustained (up to two cell population doubling times) compared to 
the G
2
 arrest in irradiated genetically matched MLH1−, MMR− cells. 
Again, only small differences in clonogenic survival were noted 
using HDR IR.
Because the four MLH1 MMR− cell model systems used by our 
group in these two reports (Davis et al., 1998; Yan et al., 2001) 
differ in the cell type (i.e., mouse and different human tumor ori-
gins), in the genetic/epigenetic basis of MLH1 deficiency, and in 
the techniques used to establish MLH1-proficient counterparts 
(human chromosome 3 transfer or 5-deoxyazacytidine treatment 
for demethylation), our combined data suggest that the reduced 
and shorter G
2
 arrest following IR is a general characteristic of 
MLH1 MMR deficiency. In our initial study, (Davis et al., 1998) we 
also examined the role of p53 in this altered G
2
 arrest by knocking-
out p53 function with E6 protein in the MLH1− HCT116 and the 
MLH1+ HCT116/3–6 cell lines. The presence or absence of the p53 
protein did not affect the G
2
 arrest in the HCT116 cell system. By 
using two additional MLH1− human tumor cell lines that differ in 
p53 status (negative protein expression in A2780/CP70 and positive 
in RKO) in the more recent study, (Yan et al., 2001) we confirmed 
that the p53 protein does not have a significant impact on the G
2
 
cell cycle response to HDR IR damage in MLH1− and MLH1+ cells. 
However, p53 activation may be important in MMR processing of 
certain chemically induced mismatches leading to both apoptotic 
and autophagic cell deaths as we described (Zeng et al., 2007) and 
illustrate in Figure 1 for 6-TG treatment.
We also examined a MSH2−, MMR− human endometrial cancer 
cell system (HEC59) to determine whether MSH2 has an effect on 
G
2
 arrest following IR treatment (Yan et al., 2001). We found that the 
MSH2-deficient HEC59 cells show the classical damage-tolerance 
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(i.e., HT29 colon cancer and U251 glioblastoma cell lines; Yan 
et al., 2009). In addition, a similar result is found in HEC59 
endometrial cancer cells, (Yan et al., 2009) which are MSH2−, 
suggesting that functional MMR is not a  prerequisite for MLH1 
protein accumulation during prolonged LDR IR. Importantly, 
the increase in MLH1 protein levels seems to result from reduced 
MLH1 protein degradation.
The other DNA repair protein found to be altered in this LDR 
IR study was Rad51, which in contrast to MLH1, was found to 
be progressively decreased in response to prolonged LDR IR (Yan 
et al., 2009). Rad51, a strand transferase, is a key component in 
homologous recombination and overexpression of Rad51 results 
in increased homologous recombination capability. MMR is pre-
viously reported to be involved in homologous recombination 
(Surtees et al., 2004) because mismatches can be produced within 
the heteroduplex generated by strand exchange during DNA rep-
lication to allow bypass of unrepaired damage. During prolonged 
LDR IR, low levels of continuous DNA damage (including low levels 
of DSBs) result, as manifested by a sustained elevation of p53 and 
p21 proteins but without significant γH2AX induction (Yan et al., 
2009). Because homologous recombination is one of the major 
repair pathway of IR-induced double-strand breaks and is most 
active during late-S-phase, our data showing the inverse correla-
tion of MLH1 and Rad51 protein levels during LDR IR (Yan et al., 
2009) lead us to speculate that altered MLH1 protein degradation 
(with enhanced MutLα levels) affects homologous recombination 
through reduced expression of Rad51. From a clinical-translational 
perspective, our data suggest that MLH1-proficiency may decrease 
cancer susceptibility following prolonged LDR IR, and may also 
increase the efficacy of localized prolonged LDR IR as used in cancer 
cells showed enhanced cytotoxicity during and following LDR IR 
via both apoptotic and autophagic death pathways and a dose rate 
and total IR  dose-dependent G
2
/M arrest, (Yan et al., 2009) similar 
to other reports (DeWeese et al., 1998; Zeng et al., 2000).
Interestingly, we also found an increased late-S-phase population 
in the MLH1+ cells during protracted LDR IR, (Yan et al., 2009) that 
is not previously reported. This late-S-phase accumulation is not 
easy to recognize without nocodazole treatment. Indeed, it is only 
made possible when the nocodazole-trapped mitotic cell popula-
tion increases significantly, resulting in a shift of the G
2
/M peak to 
the right. Previously, Brown et al. (2003) have reported that MMR 
is required for the S-phase checkpoint following HDR IR. Our data 
also suggest a role for MLH1 in slowing late-S-phase progression 
during prolonged LDR IR, (Yan et al., 2009) although the mechanism 
underlying this late-S-phase accumulation in MLH1+ cells remains to 
be fully elucidated. We speculate that there may be interplay between 
MLH1 protein (or MMR) and homologous recombination in the 
late-S-phase during prolonged LDR IR as the persistent LDR IR 
leads to continuous generation of DNA damage and homologous 
recombination is believed to occur mainly in the late-S and G
2
-phases 
(Yan et al., 2009).
In our study, we did not find significant changes in the protein 
levels of many different DNA repair proteins during prolonged 
LDR IR (Yan et al., 2009). However, we did find that the levels 
of MLH1 protein and its dimeric partner PMS2 protein were 
elevated (up to four-fold increase in MLH1) after protracted 
LDR IR in the MLH1+ cells, whereas the levels of MSH2 pro-
tein and its dimeric partner MSH6 protein were concomitantly 
reduced. These results using the isogenic HCT116 cell lines were 
confirmed in two additional MLH1+ human cancer cell lines 
Figure 3 | Current stains of experimental biology model of MMr processing of ir-induced base damage following acute iiDr and prolonged LDr ir exposures.
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The MMR status of the cells is important for determining both 
the amount of IUdR incorporation and the cell cycle response to dif-
ferent amounts of IUdR incorporation. The models at the molecular 
level will provide the amount of IUdR incorporation, which will then 
be used in the cell cycle models to determine the corresponding cell 
cycle kinetics. The response to IR is dependent on both the amount 
of IUdR incorporated into the DNA as well as the cell cycle state when 
the cells are irradiated. The objective is to then optimize this response 
by using the computational models we are developing both at the 
molecular level and at the cell population level. The models will pro-
vide the time when the maximum difference in the amount of IUdR 
incorporation into DNA between MMR− and MMR+ cells occurs, 
with MMR− cells having incorporated more IUdR than MMR+ cells. 
At the same time, the cell cycle models will provide information on 
the percentage of cells in the different cell cycle states, which will be 
used to determine the time when most of the MMR− cells are in G
2
 
phase where they are most sensitive to IR, and when most of the 
MMR+ cells are in S-phase where they are least sensitive to IR. The 
main objective of such optimization is to maximize the cell death in 
MMR− cells by IR while sparing the MMR+ cells.
To better understand the dynamics involved in our observed 
biochemical and molecular differential MMR processing of 6-TG 
(Figure 1) vs. IUdR (Figure 2) damage, as well as IR damage (Figure 
3), we are applying dynamic systems methods to develop an in silico 
model of MMR. The MMR process is modeled as a stochastic hybrid 
system that incorporates both the continuous and discrete dynamic 
behaviors of MMR (Figure 4), as published in the Proceedings of the 
IEEE/NIH BISTI Life Science Systems and Applications Workshop, 
brachytherapy. A summary of the MMR processing of HDR IR 
and LDR IR, including the cell cycle and cytotoxic responses, is 
illustrated in Figure 3.
developMent of in silico ModelS for MMr proceSSIng 
of Iudr and/or Ir daMage and for MMr effectS on 
cell cycle kInetIcS followIng Iudr and/or Ir daMage 
current StatuS In the developMent of an in silico Model of 
MMr daMage proceSSIng
We are developing computational models to quantitatively analyze the 
effects of MMR processing on the effectiveness of the treatment strate-
gies where IUdR and/or IR are used. The models are developed at two 
different levels, at the molecular level and at the population level. The 
models that are being developed at the molecular level are introduced 
in this section, and the population level cell cycle models are discussed 
in Section B. The molecular level models are being developed to study 
the dynamics of MMR damage processing. We have first modeled 
the dynamics of the recognition sub-process of the MMR pathway 
as discussed below. We are currently working on incorporating the 
dynamics of the excision and repair synthesis sub-processes to this 
model. The complete model of the MMR process will be used to study 
the time course of the damage repair dynamics by the MMR pathway. 
The outputs of the entire MMR pathway model are the amount of 
damage repaired by the pathway as well as the remaining unrepaired 
damage in the DNA. This quantitative time course information on the 
amount of repaired and unrepaired DNA damage will then be used in 
combination with the cell cycle models discussed in Section B in order 
to determine the cellular responses under different damage conditions.
Figure 4 | Modeling framework: hybrid model human DNA MMr.
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blot analysis where experimental data are obtained as relative rather 
than absolute measurements. These data cannot be used directly 
for estimating model parameters.
Given the limitations of the existing literature, we have recently 
begun to study the initial step in MMR processing (i.e., MutSα 
binding) of G:IU vs. G:T mispairs using a purified protein system 
as described by the Modrich laboratory (Constantin et al., 2005). 
To date, we have made modest progress in generating these prelimi-
nary experimental data and subsequent computational modeling 
as described below. To begin to generate the experimental data, we 
were required to adapt and/or modify several techniques from the 
literature as follows.
First, as opposed to the construction of a G:T mismatch, nucleo-
tide based mismatches such as G:IU require the use of synthetic 
oligomers, as IUdR cannot be produced in cells or by PCR methods. 
Consequently, we developed several more efficient modifications to 
the method of Wang and Hays (2006) for construction of a G: IU 
incorporated plasmid substrate. Our modifications include the use 
of a different combination of endonuclease enzymes, Nhe1/BciV1, 
and two new redesigned plasmids, pWDAH1A and pWDSH1B 
(Du, 2011). We reported a high efficiency (up to 90%) of these 
mismatch substrates and confirmed recognition using a functional 
assay (Du, 2011).
Second, for MutSα heterodimer purification, we obtained a 
MutSα expression baculovirus from the Modrich lab and used 
their purification strategy (Genschel, 2006). Briefly, SF9 insect 
cells (Invitrogen, Carlsbad, CA, USA) expressing MutSα protein, 
infected at a MOI (multiplicity of infection) of two were grown 
in a 1 l flask containing 300 ml of serum-free HyQ SFX media 
(HyClone, Logan, UT, USA) at 27°C. After 60 h of incubation, 
cells were collected by centrifugation, and the cell pellet was 
resuspended Logan, UT pended in media. This was followed by 
a four-step column purification involving initial passage through 
a ssDNA-cellulose column (USB, Cleveland, OH, USA), then 
through a HiTrap Q FF anion exchange column (GE Healthcare, 
Piscataway, NJ, USA) in an AKTA purifier 10 UPC machine (GE 
Healthcare), and finally, twice through a Mono Q 5/50 GL column 
(GE Healthcare). At each step, western blotting and Coomassie 
2007 (Gurkan et al., 2007b). As indicated above, the MMR process 
involves a finite number of sub-processes, each involving biochemi-
cal dynamics for recognition, excision, and repair. Consequently, a 
stochastic hybrid systems modeling framework is the most appropri-
ate for modeling the DNA MMR pathway because of the discrete- 
and continuous-state dynamics of each of the MMR sub-processes. 
The discrete-states in the model are the recognition, excision, and 
repair synthesis sub-processes, (Hespanha, 2006) that are defined 
in terms of the dynamics of an interacting multiprotein system that 
defines the biochemistry of the pathway. For the study of cancer 
treatment with chemotherapy and/or IR, another important dis-
crete-state needs to be included in this modeling framework, the cell 
death state. Understanding the conditions that will drive the process 
to cell death is crucial for effective translational research aimed at 
developing more effective cancer therapeutics.
The hybrid model (Figure 4) has the following states: binding 
of MutS, binding of MutL, excision of the DNA fragment, DNA 
resynthesis and filling of the nick by ligation together with any fault 
states that are associated with failure modes that can occur in the 
process. For example, the fault states can be used to model how 
MMR+ cells are transformed to MMR− cells, and this will facili-
tate a more detailed investigation into how various types of MMR 
defects can be detected and diagnosed using in vitro and in vivo 
experimental data. Because the process evolves probabilistically, 
for example the binding of the MutS and MutL proteins are ran-
dom events, a stochastic hybrid modeling framework is the most 
appropriate. Further, the uncertainty of enzyme concentrations and 
activities that define the biochemical reactions of the pathway is best 
modeled using non-deterministic (probabilistic) parameter sets. 
In this model, the ATP activity for the binding of MutS and MutL, 
the excision of the DNA, the resynthesis, and the ligation process 
have continuous dynamics defined by the biochemical activities of 
the corresponding enzymes. The transitions between the discrete-
states in the MMR process can be modeled as discrete events where 
the transition rules (switching conditions) are defined by protein 
concentrations or possibly in terms of the types of conformational 
changes. The conditions that drive the cells into the cell death state 
of the hybrid model are also studied because of their importance 
in cancer therapeutics.
A crucial component in the modeling process is the laboratory 
data that are necessary for model development. The temporal reso-
lution (sampling) as well as the quantification of the data are critical 
items that need to be addressed. The main problem in the current 
cancer biology literature is the lack of appropriate time course data 
with the required time resolution and level of quantification. This 
limitation makes it difficult to develop realistic models because 
the parameters estimated using the available experimental data are 
generally far from being biologically meaningful.
Another major problem is the multiple and diverse sources of 
experimental data for the MMR pathway proteins. The activities 
for the enzymes that are measured often differ by orders of magni-
tude among different experiments and sources. In order to obtain 
biologically realistic and meaningful models, it is important that 
the data are obtained from the same laboratory under the same 
experimental conditions. Quantification of the experimental data 
is another problem that needs to be resolved. This problem arises 
especially when protein concentrations are studied using western 
Figure 5 | SDS-PAge gel of Purification results for MutSa (MSH2 – MSH6).
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(The MathWorks, Inc., Natick, MA, USA) to implement SSA. The 
 simulations need to be repeated, and the average output curve needs 
to be calculated from the outputs of individual simulations. We have 
simulated the binding and unbinding reactions until they reach 
the steady-state for 200 times, and we have averaged the outputs 
of these 200 simulations.
The simulation results agree with the experimental data that 
show that the binding affinity of MutSα to the normal substrate 
without mispairs is low, and it is highest for the substrate with G:T 
mispairs (Figure 6). The binding profile of MutSα to a substrate 
with a G:IU is very similar to a substrate with G:T mispair. The 
simulation results show that, at steady-state, the amount of MutSα 
bound to DNA is highest for DNA containing G:T mispairs indi-
cating that the affinity of MutSα is highest for DNA containing 
G:T mispairs. The amounts of MutSα bound to DNA containing 
G:IU mispairs at steady-state is comparable to the amounts in case 
of G:T mispairs agreeing with the experimental results showing 
that the affinities in the case of G:T mispairs and G:IU mispairs 
are comparable. The amount of MutSα bound DNA with G:C as 
the control at steady-state is almost half of the amounts for DNA 
with G:T and G:IU mispairs, agreeing with the experimental results 
indicating low affinity to DNA containing normal G:C pairs.
The stochastic simulations using data obtained from purified 
protein experiments are used to computationally model the kinetics 
of the recognition of different mispairs by the DNA MMR path-
way. Both the experimental data and the simulation results showed 
that the MMR system recognizes the damage created by IUdR in 
the DNA in the form of G:IU mispairs. We are currently working 
toward the development of a computational model for the dynam-
ics of the complete MMR pathway.
The iterative nature of our systems biology approach to develop 
in silico models to study MMR processing of drug and/or IR damage 
is described as follows. The first stage of the model development is 
parallel to the wet-lab reconstitution of the MMR pathway using 
a purified protein system. In this stage, the enzymatic steps of the 
pathway are reconstituted in vitro to study the kinetics of the enzy-
matic activities. Although the MMR pathway has been reconstituted 
before in the literature, (Constantin et al., 2005; Zhang et al., 2005) 
the kinetics of the enzymes were not measured in these  experiments. 
Blue staining were used to identify the target proteins. Final purity 
was estimated to be ≥95% as illustrated in the 1D SDS-PAGE gel 
silver staining in Figure 5.
Third, we used the surface plasmon resonance (SPR) technique 
to generate our preliminary data on the association and dissocia-
tion kinetics of MutSα binding to the dsDNA 120 bp mismatch 
substrates containing the G:T and G:IU mispairs described above, 
as well as a G:C control. The application of the principles of SPR to 
measure the kinetics of bimolecular interactions are well described 
in the literature, (Myszka, 1997) and the SPR protocol from the 
Modrich lab was used (Blackwell et al., 2001). Briefly, a Biacore 
3000 System and a Sensor Chip SA (GE Healthcare) were used 
(Blackwell et al., 2001). The 5′ end of the mismatch substrates 
were biotynlated to facilitate attachment to the sensor surface and 
MutSα with ATP (1:1) was injected at a flow rate of 10–40 μl/min 
followed by dissociation time of at least 2 min. The association 
and dissociation constants, as well as the equilibrium dissociation 
constants were calculated using Biacore evaluation software and 
the results are summarized in Table 1.
Next, stochastic simulations are used to study the binding of 
MutSα to mispairs where the rate constants are obtained from the 
Biacore analysis. The reactions used in the simulations are as follows:
MutSα + DNA (with G:C or G:T or G:IU) ↔ MutSα:DNA.
The association and dissociation rate constants used in the 
simulations are given in Table 1. The substrate concentration was 
taken to be 5 nM (12612 molecules for a volume of 4.2 × 10−12l), 
and the MutSα concentration was 10nM (25224 molecules). The 
simulation results are shown in Figure 6.
We have used the exact stochastic simulation algorithm (SSA) 
of Gillespie (1976, 1977) originally developed for the analysis of 
chemical reaction systems where the number of molecules of some 
of the reactants can become small. When the molecule numbers are 
large, the SSA results are the same as the deterministic ordinary dif-
ferential equation (ODE) system solutions. The applicability of the 
SSA to reactions with small or large numbers of molecules makes it 
an attractive method to use, because the molecule numbers in the 
cell can become small, and the ODE modeling approach is not valid. 
The SSA generates numerical realizations of the stochastic processes 
defined by a chemical master equation using a Monte Carlo simu-
lation strategy. The algorithm is based on the calculation of the 
probability that a particular reaction occurs on an infinitesimal time 
interval. The output of the stochastic simulation is the time profiles 
of the molecular concentrations of the reactants. For MutSα binding 
reactions, the output is the number of mispairs bound by MutSα.
Details of the derivations and calculations involved in SSA can 
be found in detail in prior publications from Gillespie (1976, 1977). 
We summarize the steps in Table 2, and we have used Matlab® 
Table 1 | Association and dissociation rate constants (ka and kd), and 
equilibrium dissociation constant (KD) for substrates that contain g:C, 
g:T, or g:iu obtained from surface plasmon resonance analysis.
 g:C g:T g:iu
ka(1/Ms) 3.38 × 10
4 2.08 × 104 2.21 × 104
kd(1/s) 3.48 × 10
−3 7.97 × 10−4 9.36 × 10−4
KD(M) 1.03 × 10
−7 3.83 × 10−8 4.24 × 10−8
Figure 6 | The stochastic simulation results (mean curves) for the 
binding of MutSa to substrates that contain g:C (blue curve), g:T (green 
curve), or g:iu (red curve).
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molecular reactions are developed using a bottom-up mechanistic 
approach. However, the continuous evolution of an ever-increasing 
number of cell cycle regulatory proteins and protein complexes, 
with both positive and negative feedbacks, complicates the adapt-
ability of these deterministic models to realistic biological envi-
ronments (Cain and Chau, 1997; Bernard et al., 2003; Chen et al., 
2004; Novak and Tyson, 2004; Toettcher et al., 2009). Additionally, 
these models rely heavily on time sensitive quantitative kinetic data, 
often requiring multiple repeated measurements over time intervals 
of seconds to minutes (Chen et al., 2004; Toettcher et al., 2009; 
Ubezio et al., 2009).
In contrast, probabilistic models developed using a top-down 
approach to cell cycle dynamics incorporate quantitative measure-
ments from flow cytometry and other related techniques over time 
intervals of hours to days. We recently published such a top-down 
approach to assess differences in cell cycle dynamics in MMR− and 
MMR+ human tumor cell populations with and without IUdR 
treatment (Gurkan et al., 2007a). In this prior study, we analyzed 
differences in clonogenic survival,% IUdR–DNA cellular incorpo-
ration and cell cycle kinetics by flow cytometry using initially syn-
chronized isogenic MMR+ and MMR− HCT116 human colorectal 
cancer cell lines, treated with varying concentrations of IUdR 
(0–30 μM) for up to one cell cycle (cell doubling) time (24 h). We 
found that initially synchronized MMR− cells have a shortened 
(2 hour) G
2
/M phase, even without IUdR treatment, compared to 
MMR+ cells. The additional damage to IUdR (principally mani-
fested as G:IU mispairs) caused an IUdR-dose-dependent increase 
in the G
2
/M arrest in MMR+ cells during the first cell cycle, while 
IUdR treated MMR− cells showed a late S-phase delay as well. 
We speculated that the late S-phase delay represented signaling 
damage recognition of the persistent (unrepaired) G:IU mispairs 
in MMR− cells by other DNA repair systems, including base exci-
sion repair and/or homologous recombination (Taverna et al., 
2003; Turner et al., 2006; Kinsella, 2009). However, we found 
It is crucial to quantify these dynamics for  development of the 
computational model of the MMR process. Although some of these 
enzyme activities can be found in the literature, not all of these 
activities are measured in the same experimental setup. It is very 
important for dynamic system modeling of the MMR process that 
the data are consistent and are obtained from the same experimen-
tal source. Model parameters (e.g., kinetic constants and propen-
sities of reactions) are then directly calculated from the available 
experimental measurements. The model developed for the recon-
stitution system is then used to study the MMR process dynamics 
through a structured set of hypotheses driven in silico experiments.
In the second stage, nuclear extracts are used in the experiments 
in place of purified proteins. These experiments provide the data 
that are necessary to analyze the dynamics of the MMR process in 
cell lines. In the third stage of modeling, data from cellular system 
experiments are used to further refine the models. Simulations 
for different initial damage concentrations and different protein 
concentrations are used to capture actual experimental outputs 
and to relate cell repair capacity to the amount of damage. These 
in silico scenarios are tested and verified by wet-lab experiments. 
Experimental results are used to modify and validate the model 
through an iterative process, and the final cellular models can then 
be used to accurately predict the dynamics of repair responses to 
different treatment strategies.
current StatuS In the developMent of an in silico Model of 
MMr effectS on cell cycle kInetIcS followIng Iudr and/or Ir 
daMage
Cell cycle kinetics can be modeled using deterministic and probabil-
istic computational approaches. Clyde et al. (2006) provide a review 
of different cell cycle models and illustrate how mathematical mod-
eling can be used to identify new targets for drug and small molecule 
development in cancer and other diseases of unregulated prolifera-
tion. In general, deterministic ODE models of biochemical and 
Table 2 | The steps in the SSA algorithm and the implementation details.
SSA steps implementation
Initialization step: set number of reactions (M), stochastic reaction 
constants (c1. …, cM), initial molecular population numbers 
(x1,…,xN), set time variable t and reaction counter n to 0
M = 2 (reaction 1 is the binding reaction and reaction 2 is the unbinding reaction) c1 
(unit: (molecules*s)−1) = 1.34 × 10−8 for G:C pairs, 8.24 × 10−9 for G:T pairs, 8.76 × 10−9 
for G:IU pairs c2 (unit: s
−1) = 3.48 × 10−3 for G:C pairs, 7.97 × 10−4 for G:T pairs, 
9.36 × 10−4 for G:IU pairs x1 = initial damage, 12612 molecules, x2 = MutSα molecules, 
25224 molecules, x3 = MutSα bound mispairs, initially set to 0 t = 0, n = 0
Step 1: calculate M reaction propensities a1…aM. The derivation of 
ai’s can be found in Gillespie (1976, 1977). Calculate the sum of ai’s 
as a0.
a1 = c1 *x1 *x2 for the reaction where MutSα (x2) binds to the mispair (x1) a2 = c2 * x3 for 
the reaction where MutSα unbinds from MutSα·DNA complex a0 = a1 + a2 (sum of ai’s)
Step 2: generate two random numbers r1 and r2 using the unit-interval 
uniform random number generator, and calculate time step τ = 1 1a r0 1ln , 
and the reaction number μ that is going to take place in the time 
interval τ using the formula ∑ < ≤ ∑−i=1 i 2 0 i=1 ia r a aµ µ1
We generate two random numbers using “rand” function in Matlab®. We have 
calculated τ and μ using the given formulas.
Step 3: increase time by the time step τ, and adjust the molecular 
population levels (molecule numbers) of the reactants according to 
the reaction μ that takes place in the time step τ. Increase the 
reaction counter n by 1 and return to step 1. 
t = t + τ An example for the adjustment of molecule numbers: If μ = 1, that means the 
binding reaction took place in the time step τ, so the molecule numbers of MutSα (x2) 
and mispairs (x1) need to be decreased by 1 (x1 = x1 – 1, x2 = x2 – 1), and the molecule 
number of MutSα bound mispair (x3) needs to be increased by 1 (x3 = x3 + 1). 
n = n + 1
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A differential cell cycle response is also seen following HDR IR 
alone. Compared to untreated cells, IR treated MMR− cells show a 
more pronounced (3×) G
2
/M arrest in cycle one while also showing 
a longer (2 h) G
1
 arrest. In contrast, IR treated MMR+ cells have a 
similar G
1
 arrest and only a 2× increase in the G
2
/M arrest in the 
first cell cycle compared to untreated MMR+ cells. However, since 
the G
2
/M arrest following 5 Gy is so long in the first cell cycle, our 
sensitivity analyses of IR effects during the second cell cycle are 
limited by the overall time (28 h) of data sampling. No differences 
in clonogenic survival were found over a dose range of 2–10 Gy 
in these isogenic MMR+ and MMR− HCT116 cells, as previously 
reviewed (Jiricny, 2006; Kinsella, 2009). Future experiments will 
require lower IR doses (1–3 Gy/min) and possibly shorter sampling 
intervals over a longer time. We also plan to evaluate the effects of 
LDR IR on cell cycle kinetics of MMR+ vs. MMR− cells.
In summary, there are significant changes in cell cycle dynamics 
with IUdR alone, HDR IR alone, and IUdR + IR in both MMR+ and 
MMR− human tumor cells, based on our flow cytometry data and 
subsequent probabilistic modeling. Our current plan is to further 
develop these probabilistic models of IUdR ± IR interactions using 
data derived from in vivo systems of HCT116 (and other) human 
tumor cell lines as xenografts in athymic mice which will also allow 
for assessment of treatment effects (toxicities) on normal tissues 
(which are MMR+) to calculate a therapeutic index (Gurkan et al., 
2007b).
One clear advantage to the in vivo or clinical use of IUdR to target 
MMR− tumors for radiosensitization is that the drug can also be used 
to measure tumor cell kinetics (Rodriguez et al., 1994). By measur-
ing the labeling index (LI) using immunohistochemistry and the 
duration of S-phase (Ts) by flow cytometry at any time point, the 
potential tumor doubling time (Tpot) can be calculated using the 
formula: Tpot = Ts/LI × 0.9 (Rodriguez et al., 1994). We have previ-
ously hypothesized that for IUdR to be an effective in vivo/clinical 
radiosensitizer, an IUdR dosing schedule is needed to “label” nearly 
all (>95%) tumor cells with up to 5% IUdR–DNA cellular incor-
poration (Rodriguez et al., 1994; Kinsella, 1996). Using HCT116 
MMR− tumor xenografts, we found that continuous intravenous 
IUdR infusions with a steady-state plasma concentration of 1 μM 
only modest (< <1 log) differences in clonogenic survival in the 
clinically relevant range of IUdR concentrations (1–10 μM) with 
lower survival in MMR− cells. In contrast, we have found marked 
(>1 log) decreased survival in MMR+ cells compared to MMR− 
cells following treatment with other nucleoside analogs, such as 
6-TG and no cell cycle changes (particularly G
2
/M arrest) until 
at least the second or third cell cycle following drug treatment 
(Figure 1; Berry and Kinsella, 2001; Meyers et al., 2001; Yan et al., 
2003; Kinsella, 2009).
Using our experimental flow cytometry and IUdR–DNA incor-
poration data, we developed two computational models (Gurkan 
et al., 2007a). The first was a stochastic model of the progression 
of the cell cycle states for one cell cycle in synchronized MMR+ and 
MMR− HCT116 cell populations (Figure 7). The second model 
defined the relation between the % of cells in the different cell cycle 
states and the corresponding% IUdR–DNA incorporation (as a sur-
rogate measure of IUdR-mediated radiosensitization) at any time 
during the first cell cycle period. In a more recent study (unpub-
lished), we adapt and modify our probabilistic cell cycle model to 
study the effects for up to two cell cycles of IUdR alone (10 μM), IR 
alone (5 Gy), and the combined use of IUdR followed by HDR IR. 
In our experimental design, HDR IR was delivered at three specific 
time intervals following release from synchronization when the 
cell populations were becoming asynchronous but a majority were 
still in G
1
 (13 h), S (16 h), or G
2
/M (21 h), respectively. Following 
IR, cells were sampled hourly using flow cytometry until hour 28 
from release. To the best of our knowledge, this study is the most 
comprehensive experimental/computational analysis of a drug-IR 
interaction by flow cytometry for 1–2 cell population doublings.
We confirmed our prior observations (Gurkan et al., 2007a) of 
differences in cell cycle dynamics comparing MMR+ and MMR− 
cell populations with and without IUdR treatment. Untreated 
MMR− cells exit G
1
 into S ∼2 h faster than MMR+ cells during 
the first and second cell cycles while also demonstrating a shorter 
G
2
/M arrest. Following IUdR treatment, MMR+ cells show a more 
pronounced G
2
/M arrest in both the first and second cycles, while 
a more pronounced G
1
 arrest is found in MMR− cells during the 
second cell cycle.
Figure 7 | (A) stochastic in silica model of the cell cycle (B) example probability density function (C) cell cycle model outputs compared to experimental data p, 
experimental data (−); model outputs: GI (∆), S (t), and G2 ( )¨ (adapted from reference Gurkan et al., 2007a).
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